Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 12 studies | 29% ± 10% | |
natural killer cell | 9 studies | 36% ± 19% | |
B cell | 8 studies | 33% ± 12% | |
microglial cell | 8 studies | 32% ± 11% | |
CD16-positive, CD56-dim natural killer cell, human | 7 studies | 30% ± 19% | |
T cell | 6 studies | 37% ± 8% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 33% ± 14% | |
CD4-positive, alpha-beta T cell | 4 studies | 30% ± 10% | |
CD8-positive, alpha-beta T cell | 4 studies | 31% ± 14% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 30% ± 11% | |
macrophage | 3 studies | 21% ± 3% | |
lymphocyte | 3 studies | 60% ± 11% | |
leukocyte | 3 studies | 47% ± 11% |
Insufficient scRNA-seq data for expression of CARD11 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 925.15 | 578 / 578 | 84% | 21.99 | 966 / 1155 |
bladder | 90% | 1301.48 | 19 / 21 | 85% | 39.62 | 427 / 504 |
pancreas | 73% | 147.61 | 241 / 328 | 94% | 53.35 | 168 / 178 |
stomach | 81% | 250.23 | 290 / 359 | 70% | 17.29 | 201 / 286 |
kidney | 83% | 311.92 | 74 / 89 | 67% | 10.19 | 606 / 901 |
thymus | 89% | 314.05 | 581 / 653 | 61% | 11.99 | 367 / 605 |
brain | 76% | 180.21 | 2013 / 2642 | 65% | 5.71 | 456 / 705 |
breast | 80% | 185.60 | 365 / 459 | 54% | 5.24 | 602 / 1118 |
ovary | 68% | 150.57 | 122 / 180 | 62% | 9.61 | 266 / 430 |
uterus | 65% | 117.35 | 110 / 170 | 59% | 11.54 | 269 / 459 |
intestine | 63% | 926.65 | 609 / 966 | 59% | 16.22 | 312 / 527 |
adrenal gland | 91% | 223.42 | 235 / 258 | 29% | 4.31 | 67 / 230 |
esophagus | 44% | 96.71 | 635 / 1445 | 72% | 21.04 | 131 / 183 |
prostate | 92% | 302.60 | 225 / 245 | 20% | 1.43 | 99 / 502 |
liver | 85% | 161.74 | 191 / 226 | 19% | 4.15 | 77 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 171.95 | 29 / 29 |
spleen | 100% | 6089.52 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 35.73 | 1 / 1 |
peripheral blood | 100% | 4211.48 | 926 / 929 | 0% | 0 | 0 / 0 |
adipose | 83% | 197.53 | 1003 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 82% | 12.46 | 37 / 45 |
skin | 34% | 50.34 | 623 / 1809 | 43% | 6.71 | 204 / 472 |
blood vessel | 55% | 127.34 | 730 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 44% | 7.07 | 35 / 80 |
heart | 18% | 26.11 | 156 / 861 | 0% | 0 | 0 / 0 |
muscle | 1% | 1.19 | 8 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0045577 | Biological process | regulation of B cell differentiation |
GO_0046037 | Biological process | GMP metabolic process |
GO_0051260 | Biological process | protein homooligomerization |
GO_0045061 | Biological process | thymic T cell selection |
GO_0050862 | Biological process | positive regulation of T cell receptor signaling pathway |
GO_0045580 | Biological process | regulation of T cell differentiation |
GO_0035739 | Biological process | CD4-positive, alpha-beta T cell proliferation |
GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
GO_0031295 | Biological process | T cell costimulation |
GO_0046710 | Biological process | GDP metabolic process |
GO_0048872 | Biological process | homeostasis of number of cells |
GO_0032743 | Biological process | positive regulation of interleukin-2 production |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0030890 | Biological process | positive regulation of B cell proliferation |
GO_2000563 | Biological process | positive regulation of CD4-positive, alpha-beta T cell proliferation |
GO_0042100 | Biological process | B cell proliferation |
GO_0030183 | Biological process | B cell differentiation |
GO_0038202 | Biological process | TORC1 signaling |
GO_0001772 | Cellular component | immunological synapse |
GO_0005886 | Cellular component | plasma membrane |
GO_0045121 | Cellular component | membrane raft |
GO_0032449 | Cellular component | CBM complex |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0050700 | Molecular function | CARD domain binding |
GO_0004385 | Molecular function | guanylate kinase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CARD11 |
Protein name | Caspase recruitment domain family member 11 Caspase recruitment domain-containing protein 11 Caspase recruitment domain-containing protein 11 (CARD-containing MAGUK protein 1) (Carma 1) |
Synonyms | CARMA1 |
Description | FUNCTION: Adapter protein that plays a key role in adaptive immune response by transducing the activation of NF-kappa-B downstream of T-cell receptor (TCR) and B-cell receptor (BCR) engagement . Transduces signals downstream TCR or BCR activation via the formation of a multiprotein complex together with BCL10 and MALT1 that induces NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways . Upon activation in response to TCR or BCR triggering, CARD11 homooligomerizes to form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerization of BCL10 and subsequent recruitment of MALT1: this leads to I-kappa-B kinase (IKK) phosphorylation and degradation, and release of NF-kappa-B proteins for nuclear translocation . Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner . Promotes linear ubiquitination of BCL10 by promoting the targeting of BCL10 to RNF31/HOIP . Stimulates the phosphorylation of BCL10 . Also activates the TORC1 signaling pathway . . |
Accessions | A0A192GRC6 E2QRC0 Q9BXL7 ENST00000356408.3 H7BY05 A0A192GQG0 ENST00000396946.9 A0A192GQF6 ENST00000355508.3 A0A192GQE0 A0A192GRD0 A0A192GQM1 |